-
Mashup Score: 6FDA approves KalVista's Ekterly for hereditary angioedema - 1 month(s) ago
The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).
Categories: General Medicine NewsTweet
-
Mashup Score: 3Flu vaccine strategy on the line as new US leaders anticipated to take charge - Pharmaceutical Technology - 8 month(s) ago
Public health experts are anticipating a changing discourse following RFK Jr’s appointment as head of HHS.
Categories: General Medicine News, Infectious DiseaseTweet-
In this piece I’m quoted about multiple aspects of vaccination, vaccine hesitancy, and the increasing power of the anti-vaccine movement https://t.co/odUbKuXvKN
-
-
Mashup Score: 0PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass - Pharmaceutical Technology - 9 month(s) ago
The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive treatment.
Categories: General Medicine News, Infectious DiseaseTweet-
“I think HIV vaccine research is in a very difficult position, and you have to ask, “who would fund it”? If you wanted to do an efficacy trial now, you would have to offer long-acting PrEP because it exists” https://t.co/1fZuSA3HQN
-
-
Mashup Score: 28Insulin pricing: could an e-commerce approach cut costs? - 11 month(s) ago
An e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.
Categories: General Medicine News, Hem/OncsTweet-
How did insulin prices finally come down in America. 1) Over a 20 year period, insulin list prices increased in America to 10 times the cost in other developed countries. https://t.co/wr3sgO6obc https://t.co/1OfTNdULBK
-
-
Mashup Score: 8NICE recommends BeiGene’s marginal zone lymphoma tablet - 1 year(s) ago
The UK NICE has recommended BeiGene’s Zanubrutinib for marginal zone lymphoma (MZL) for use on the National Health Service (NHS).
Categories: General Medicine News, Hem/OncsTweet-
NICE recommends BeiGene’s MZL tablet for NHS use https://t.co/wrQjnzotLU via @PharmaTechFocus
-
-
Mashup Score: 0How NVIDIA grew with the healthcare market instead of pushing into it - Pharmaceutical Technology - 1 year(s) ago
As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.
Categories: General Medicine News, General HCPsTweet-
How @nvidia grew with the #healthcare market instead of pushing into it - As the use of #AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story. https://t.co/eSyEUT1j6D
-
-
Mashup Score: 0Outrun Therapeutics announces launch with $10m seed funding - 1 year(s) ago
Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.
Categories: General Medicine News, Future of MedicineTweet-
Outrun Therapeutics announces launch with $10m seed funding https://t.co/690IOH7xrd https://t.co/QSQ1jJHYBB
-
-
Mashup Score: 33
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
Categories: General Medicine News, Onc News and JournalsTweet-
“This is the decade for RAS,” says our Dr. Shubham Pant of advances in KRAS inhibitors for cancer treatment. Learn more: https://t.co/SVynltUwKV @DrShubhamPant #PancreaticCancer #LungCancer #EndCancer
-
-
Mashup Score: 2Norgine seeks approval for high-risk neuroblastoma treatment - 1 year(s) ago
Norgine has sought approval for eflornithine (DFMO) for the treatment of patients with high-risk neuroblastoma (HRNB).
Categories: General Medicine News, Hem/OncsTweet-
DFMO, developed from @UHCancerCenter, is now expanding its approval for neuroblastoma in the UK, Switzerland, and Australia. Congrats to Dr. Andre Backmann, who is currently at @michiganstateu. https://t.co/b9cHVhXjxZ
-
-
Mashup Score: 1Gilead's Biktarvy receives FDA expanded approval for HIV - 1 year(s) ago
Gilead Sciences has received FDA approval for an expanded indication for Biktarvy to treat HIV patients with M184V/I resistance mutations.
Categories: General Medicine News, Infectious DiseaseTweet-
“This marks Biktarvy as the first and only integrase strand transfer inhibitor (INSTI)-based single-tablet regimen recommended for people with HIV-1 (known as PWH) with resistance mutations.” https://t.co/ecBH56NX5e
-
FDA approves KalVista's Ekterly for #hereditary #angioedema: Ekterly’s efficacy was demonstrated through data from KalVista’s Phase III KONFIDENT clinical trial. https://t.co/SZ4i3pZ7rR https://t.co/rMees0J1r2